Abrass Christine K
Department of Medicine, University of Washington School of Medicine, Seattle, Wash. 98108, USA.
Am J Nephrol. 2004 Jan-Feb;24(1):46-53. doi: 10.1159/000075925. Epub 2003 Dec 30.
Dyslipidemia contributes to the rate of progression of atherosclerosis and chronic kidney disease. Also, chronic kidney disease leads to the development of secondary abnormalities in lipid metabolism that contribute to increased cardiovascular morbidity and mortality. This review presents the mechanisms that underlie this risk. The mechanisms of normal cellular lipid metabolism and the abnormalities that develop in association with inflammation are reviewed. There is a special emphasis on foam cells in the kidney and on lipid-mediated changes in intrinsic kidney cells that lead to glomerulosclerosis and interstitial fibrosis. Correlates to studies performed in whole animals and humans are included.
血脂异常会促进动脉粥样硬化和慢性肾脏病的进展。此外，慢性肾脏病会导致脂质代谢的继发性异常，进而增加心血管疾病的发病率和死亡率。本综述介绍了这种风险背后的机制。文中回顾了正常细胞脂质代谢的机制以及与炎症相关的异常情况。特别强调了肾脏中的泡沫细胞以及脂质介导的固有肾细胞变化，这些变化会导致肾小球硬化和间质纤维化。还纳入了与在整体动物和人类中进行的研究的相关性。
